Literature DB >> 17460699

Potential differentiation of human mesenchymal stem cell transplanted in rat corpus cavernosum toward endothelial or smooth muscle cells.

Y S Song1, H J Lee, I H Park, W K Kim, J H Ku, S U Kim.   

Abstract

One of the causes of erectile dysfunction (ED) is the damaged penile cavernous smooth muscle cells (SMCs) and sinus endothelial cells (ECs). To investigate the feasibility of applying immortalized human mesenchymal stem cells (MSCs) to penile cavernous ECs or SMCs repair in the treatment of ED, the in vivo potential differentiation of the immortalized human MSCs toward penile cavernous endothelial or smooth muscle was investigated. One clone of immortalized human bone marrow mesenchymal stem cell line B10 cells via retroviral vector encoding v-myc were transplanted into the cavernosum of the Sprague-Dawley rats and harvested 2 weeks later. The expression of CD31, von Willebrand factor (vWF), smooth muscle cell actin (SMA), calponin and desmin was determined immunohistochemically in rat penile cavernosum. Multipotency of B10 to adipogenic, osteogenic or chondrogenic differentiation was found. Expression of EC specific markers (CD31 or vWF protein) and expression of SMC specific markers (calponin, SMA or desmin protein) were demonstrated in grafted B10 cells. When human MSCs were transplanted into the penile cavernosum, they have the potential to differentiate toward ECs or SMCs. Human MSCs may be a good candidate in the treatment of penile cavernosum injury.

Entities:  

Mesh:

Year:  2007        PMID: 17460699     DOI: 10.1038/sj.ijir.3901539

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  30 in total

Review 1.  Stem cells: novel players in the treatment of erectile dysfunction.

Authors:  Haiyang Zhang; Maarten Albersen; Xunbo Jin; Guiting Lin
Journal:  Asian J Androl       Date:  2011-10-17       Impact factor: 3.285

Review 2.  Potential of adipose-derived stem cells for treatment of erectile dysfunction.

Authors:  Guiting Lin; Lia Banie; Hongxiu Ning; Anthony J Bella; Ching-Shwun Lin; Tom F Lue
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

Review 3.  The promise of cell-based therapies for diabetic complications: challenges and solutions.

Authors:  Yagna P R Jarajapu; Maria B Grant
Journal:  Circ Res       Date:  2010-03-19       Impact factor: 17.367

4.  Advances in stem cell therapy for the lower urinary tract.

Authors:  Ching-Shwun Lin
Journal:  World J Stem Cells       Date:  2010-02-26       Impact factor: 5.326

5.  Separate or combined treatments with daily sildenafil, molsidomine, or muscle-derived stem cells prevent erectile dysfunction in a rat model of cavernosal nerve damage.

Authors:  Istvan Kovanecz; Steve Rivera; Gaby Nolazco; Dolores Vernet; Denesse Segura; Sahir Gharib; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2012-09-13       Impact factor: 3.802

6.  Penile reconstruction.

Authors:  Christopher J Salgado; Harvey Chim; Jennifer C Tang; Stan J Monstrey; Samir Mardini
Journal:  Semin Plast Surg       Date:  2011-08       Impact factor: 2.314

Review 7.  Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.

Authors:  Eric Chung; Gerald B Brock
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

8.  Flk-1⁺Sca-1⁻ mesenchymal stem cells: functional characteristics in vitro and regenerative capacity in vivo.

Authors:  Yugang Li; Enshan Pan; Yu Wang; Xiaoguang Zhu; Anyang Wei
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  BDNF-hypersecreting human umbilical cord blood mesenchymal stem cells promote erectile function in a rat model of cavernous nerve electrocautery injury.

Authors:  Lujie Song; Jianqiang Zhu; Xiong Zhang; Zhiqiang Cui; Qiang Fu; Jianwen Huang; Hongkai Lu
Journal:  Int Urol Nephrol       Date:  2015-11-17       Impact factor: 2.370

10.  ROS activates JNK-mediated autophagy to counteract apoptosis in mouse mesenchymal stem cells in vitro.

Authors:  Guan-yu Liu; Xiao-xue Jiang; Xin Zhu; Wei-yang He; You-lin Kuang; Ke Ren; Yong Lin; Xin Gou
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.